50358-63-9

Basic information

• Product Name: 5-Bromoquinoxalin-6-amine
• Synonyms: 6-Amino-5-bromoquinoxaline ,98%;5-BroMoquinoxalin-6-aMine, 6-AMino-5-broMoquinoxaline;Brimonidine Related Compound (5-Bromo-6-Aminoquinoxaline);6-AMINO-5-BROMOQUINOXALINE;5-BROMO-6-QUINOXALINAMINE;5-bromoquinoxalin-6-amine;6-Amino-5-bromoquinoxaline 98%;5-Bromo-6-aminoquinoxaline
• CAS NO: 50358-63-9
• Molecular Formula: C₈H₆BrN₃
• Molecular Weight: 224.06
• EINECS: 1592732-453-0
• Product Categories: Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Quinolines, Isoquinolines & Quinoxalines;Halides;Quinolines, Isoquinolines & Quinoxalines;Chemical Amines;Amines
• Mol File: 50358-63-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 151-153°C
• Boiling Point: 367 °C at 760 mmHg
• Flash Point: 175.8 °C
• Appearance: yellow solid
• Density: 1.744 g/cm³
• Vapor Pressure: 1.4E-05mmHg at 25°C
• Refractive Index: 1.747
• Storage Temp.: Refrigerator
• PKA: 0.33±0.30(Predicted)
• CAS DataBase Reference: 5-Bromoquinoxalin-6-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromoquinoxalin-6-amine(50358-63-9)
• EPA Substance Registry System: 5-Bromoquinoxalin-6-amine(50358-63-9)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 50358-63-9(Hazardous Substances Data)

Usage

Description

5-Bromoquinoxalin-6-amine is an organic compound with the chemical formula C8H6BrN3. It is a yellow solid and is known to be a metabolite of Brimonidine, which is a medication used in the treatment of certain eye conditions.

Uses

Used in Pharmaceutical Industry:
5-Bromoquinoxalin-6-amine is used as an active pharmaceutical ingredient for the development of antiglaucoma agents, specifically in the formulation of brimonidine tartrate ophthalmic solution with a concentration of 0.15%. It helps in reducing intraocular pressure in the eyes, providing relief from glaucoma and other eye conditions characterized by high pressure within the eye.
Used in Research and Development:
As a metabolite of Brimonidine, 5-Bromoquinoxalin-6-amine may also be used in research and development for understanding the pharmacological effects, metabolism, and potential applications of Brimonidine and its derivatives in various medical fields. This can contribute to the discovery of new drugs and therapies for different health conditions.

InChI:InChI=1/C8H6BrN3/c9-7-5(10)1-2-6-8(7)12-4-3-11-6/h1-4H,10H2

Upstream product

• 6298-37-9 6-aminoquinoxaline 
• 99-56-9 4-Nitrophenylene-1,2-diamine 
• 6639-87-8 6-nitroquinoxaline 

Relevant articles and documents

Cyclic (Alkyl)(amino)carbene Ligand-Promoted Nitro Deoxygenative Hydroboration with Chromium Catalysis: Scope, Mechanism, and Applications

Transition metal catalysis that utilizes N-heterocyclic carbenes as noninnocent ligands in promoting transformations has not been well studied. We report here a cyclic (alkyl)(amino)carbene (CAAC) ligand-promoted nitro deoxygenative hydroboration with cost-effective chromium catalysis. Using 1 mol % of CAAC-Cr precatalyst, the addition of HBpin to nitro scaffolds leads to deoxygenation, allowing for the retention of various reducible functionalities and the compatibility of sensitive groups toward hydroboration, thereby providing a mild, chemoselective, and facile strategy to form anilines, as well as heteroaryl and aliphatic amine derivatives, with broad scope and particularly high turnover numbers (up to 1.8 × 106). Mechanistic studies, based on theoretical calculations, indicate that the CAAC ligand plays an important role in promoting polarity reversal of hydride of HBpin; it serves as an H-shuttle to facilitate deoxygenative hydroboration. The preparation of several commercially available pharmaceuticals by means of this strategy highlights its potential application in medicinal chemistry.

Synthesis and antiprotozoal activity of some new synthetic substituted quinoxalines

A series of 29 new quinoxalines was synthesized and evaluated in vitro against several parasites (Leishmania donovani, Trypanosoma brucei brucei, and Trichomonas vaginalis). Several of them displayed interesting activities, and particularly four quinoxaline amides showed in vitro antileishmanial properties (IC50 less than 20 μM).

Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives

A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R1and R2each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R3, R4and R5each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as reduction in peripheral pain.